Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.54 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | GHSR | Q92847 | 6/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | YAP1 | P46937 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30102438 | 1.00 | PDK1 (0.54) | PDK1PDK2PDK3PDK4GHSR | |
| SCHEMBL3902299 | 0.96 | PDK1 (0.51) | PDK1PDK2PDK3PDK4GHSR | |
| SCHEMBL3903665 | 0.94 | GHSR (0.49) | PDK1PDK2PDK3PDK4GHSR | |
| SCHEMBL3903564 | 0.92 | NPC1 (0.48) | PDK1PDK2PDK3PDK4GHSR | |
| SCHEMBL17321358 | 0.91 | HRH3 (0.53) | PDK1PDK2PDK3PDK4GHSR | |
| SCHEMBL3905150 | 0.88 | GHSR (0.45) | PDK1PDK2PDK3PDK4GHSR | |
| SCHEMBL13957119 | 0.86 | DHODH (0.45) | PDK1PDK2PDK3PDK4GHSR | |
| SCHEMBL3907882 | 0.85 | TACR1 (0.48) | GHSRSRD5A1DHODHGPR119MAOA | |
| SCHEMBL3902842 | 0.84 | PTPN1 (0.47) | PDK1PDK2PDK3PDK4GHSR | |
| SCHEMBL3912242 | 0.84 | POLB (0.43) | PDK1PDK2PDK3PDK4GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391666-B2 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| CN-112384506-B | Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20210188806-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-24 | — | — | US | disclosed |
| US-20210188806-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-24 | — | — | US | disclosed |
| EP-3795567-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2021-03-24 | — | — | EP | disclosed |
| CN-112384506-A | Indoline-1-formamide compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-110483482-A | Indoline -1- Carbox amide, preparation method and its in application pharmaceutically | BEIJING INNOCARE PHARMA TECH CO LTD | 2019-11-22 | — | — | CN | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7102007-B2 | Dihydroindole and tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1349833-B1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | disclosed |
| EP-1358162-B1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | AEBI JOHANNES (CH) | 2005-01-27 | — | — | US | disclosed |
| US-6706751-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | HOFFMAN-LA ROCHE INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1358162-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-6503907-B2 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002050041-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391666-B2 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof | FLT1, KDR, TEK | PDK1 775/4885PDK2 1092/4885PDK3 2053/4885 |
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | PDK1 484/4885PDK2 273/4885PDK3 496/4885 |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | S1PR3, S1PR2, S1PR1 | PDK1 1385/4885PDK2 1823/4885PDK3 1874/4885 |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | PDK1 484/4885PDK2 273/4885PDK3 496/4885 |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | LSS, CYP51A1, DHCR7 | PDK1 701/4885PDK2 670/4885PDK3 973/4885 |
| US-20210188806-A1 | INDOLINE-1-FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | FLT1, KDR, TEK | PDK1 775/4885PDK2 1092/4885PDK3 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.